Patrick Campbell is the managing editor of HCPLive. Formerly the editorial lead of Endocrinology Network, Practical Cardiology, and Rheumatology Network, Patrick has spent years spearheading coverage surrounding cardiometabolic health and rheumatic disease for MJH Life Sciences. He now helps to lead coverage in each of these respective areas for HCPLive. Before joining MJH Life Sciences in 2019, he spent time as a beat reporter with the Pocono Record in Stroudsburg, PA, and Star News Group in Manasquan, NJ. He also touts experience in multimedia, having spent time as a multimedia specialist with NJ Advance Media and multimedia coordinator at the Pocono Record. Follow him on Twitter @RealPatCampbell or reach him via email at PCampbell@mjhlifesciences.com.
PARAGLIDE-HF Offers Further Insight into Sacubitril/Valsartan in Heart Failure with Elevated EF
May 22nd 2023Presented at ESC HFA 2023, results of PARAGLIDE-HF detail the effects of sacubitril/valsartan on NT-proBNP and multiple clinical outcomes, relative to valsartan alone, in patients with HFmrEF or HFpEF.
Read More
Mucus Plugs in Medium- to Large-Sized Airways Increases Risk of Death in COPD Patients
May 21st 2023An analysis of the COPDGene Study presented at ATS 2023 suggests presence of mucus plugs in medium- to large-sized airways were associated with an increased risk of mortality in adjusted models.
Read More
Patients with Psoriatic Arthritis Report Greater Impact on Life than Rheumatoid Arthritis Patients
May 20th 2023An analysis of patient-reported outcomes data from more than 15,000 people with rheumatic disease sheds light on the apparent differences in impact on quality of life between psoriatic arthritis and rheumatoid arthritis.
Read More
FDA Committee Votes Against Risk-Benefit Profile of OCA 25 mg for NASH
May 20th 2023The June 22, 2023 PDUFA date for obeticholic acid 25 mg oral tablets for the treatment of precirrhotic liver fibrosis appears to be in jeopardy after a May 23, 2023 meeting of the FDA's Gastrointestinal Drugs Advisory Committee.
Read More
Long-Term Opioid Use Observed for 1 in 5 with Rheumatic or Musculoskeletal Disorders
May 17th 2023An analysis of the Clinical Practice Research Datalink provides an overview of trends and prevalence of long-term opioid use among patients with 1 of 6 rheumatic or musculoskeletal diseases using 3 definitions of long-term opioid use.
Read More
Metabolic Syndrome Could Worsen Damaging Effects of Alcohol Use on Liver
May 12th 2023Despite stable rates of heavy alcohol use, deaths from alcohol-associated liver damage have risen in the US. A new study suggests an increase in the damaging effects of alcohol use in people with metabolic syndrome could be driving this apparent increase.
Read More
Denosumab Biosimilar Shows "Promising" Efficacy, Equivalency in Phase 3 Trial
May 10th 2023A phase 3 trial comparing QL1206, a denosumab biosimilar, to the reference agent has returned results demonstrating the efficacy, safety, and pharmacokinetic equivalency of the biosimilar to the reference agent.
Read More
FDA Expands Dapagliflozin Label to Include Reducing Risk of CV Death in Heart Failure
May 9th 2023Announced just more than a year after AstraZeneca announced topline results, the FDA has approved a label expansion to include reducing cardiovascular death and HF hospitalizations for dapagliflozin based on results of the phase 3 DELIVER trial.
Read More
Study Offers Overview of Features, Outcomes, Treatment for Immune-Mediated Necrotizing Myopathy
May 8th 2023A study leveraging DoD data provides a comprehensive overview of clinical features, treatment choices, and outcomes of patients with immune mediated necrotizing myopathy relative to those of patients with other idiopathy inflammatory myopathies.
Read More
RAIL Score Provides Useful, Noninvasive Biomarker for Renal Disease Activity
May 7th 2023An analysis of data obtained from urine samples in the MUSE and TULIP-1 trial sheds new light on the clinical utility of the RAIL score for identifying disease activity and treatment responders in SLE patients with and without lupus nephritis, respectively
Read More
Study Underlines Potential of IL-6 Inhibitors for Polymyalgia Rheumatica
May 7th 2023An analysis of Medcare claims data offers clinicians an overview or the effectiveness of sarilumab and tocilizumab in second- and third-line polymyalgia rheumatica treatments relative to conventional immunomodulators, such as methotrexate or azathioprine.
Read More
Vitamin D Levels Can Influence Risk of Miscarriage, Premature Delivery in Women with Lupus
May 6th 2023An analysis of more than 250 pregnancies among women with SLE from the Hopkins Lupus Cohort provides insight into risk of adverse pregnancy outcomes based on serum 25-hydroxy vitamin D levels using real-world data.
Read More
Dermatomyositis, Polymyositis Linked to Doubling in Risk of Mortality in Heart Failure Patients
May 6th 2023An analysis of the National Inpatient Sample offers a deep dive into the risk of adverse outcomes associated with presence of polymyositis or dermatomyositis among patients with congestive heart failure.
Read More
Large Vessel Vasculitis Increases Risk of Cardiovascular Events, Renal Injury in Atrial Fibrillation
May 5th 2023An analysis of more than 1 million AFib hospitalizations suggests those with large vessel vasculitis had a nearly 2-fold increase in risk of acute myocardial infarction and a more than 9-fold increase in risk of acute kidney injury.
Read More
Renal Biopsy Data Supports Long-Term Voclosporin Use for Lupus Nephritis
May 5th 2023Data from an analysis of kidney biopsies from the AURORA 2 trial presented at CCR East 2023 offer new insight into the long-term histological impact of voclosporin use on renal function in patients with lupus nephritis.
Read More
Hour-Long Endoscopic Procedure Could Eliminate Need for Insulin in Type 2 Diabetes
May 4th 2023New research from a first-in-human study of a novel procedure involving electroporation of the superficial layer of the mucosa in the small intestine could help eliminate need for insulin in some people with type 2 diabetes.
Read More
Depression or Anxiety During Pregnancy Could Increase Type 1 Diabetes Risk for Offspring
May 4th 2023An analysis of more than 1.8 million mother-offspring pairs offers new insight into a potential association between exposure to maternal depression/anxiety during pregnancy and risk of type 1 diabetes in offspring during adolescence.
Read More